Compare VRTX & ACN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | ACN |
|---|---|---|
| Founded | 1989 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Business Services |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 129.2B |
| IPO Year | 2006 | 2015 |
| Metric | VRTX | ACN |
|---|---|---|
| Price | $434.02 | $193.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 21 |
| Target Price | ★ $539.08 | $270.81 |
| AVG Volume (30 Days) | 1.2M | ★ 5.6M |
| Earning Date | 05-04-2026 | 03-19-2026 |
| Dividend Yield | N/A | ★ 3.32% |
| EPS Growth | ★ 836.54 | 6.21 |
| EPS | ★ 15.32 | 6.47 |
| Revenue | $2,488,652,000.00 | ★ $69,672,977,000.00 |
| Revenue This Year | $10.81 | $7.15 |
| Revenue Next Year | $10.26 | $5.42 |
| P/E Ratio | ★ $29.64 | $30.35 |
| Revenue Growth | ★ 46.20 | 7.36 |
| 52 Week Low | $362.50 | $187.00 |
| 52 Week High | $510.77 | $322.86 |
| Indicator | VRTX | ACN |
|---|---|---|
| Relative Strength Index (RSI) | 35.99 | 36.43 |
| Support Level | $403.16 | $187.86 |
| Resistance Level | $465.98 | $207.98 |
| Average True Range (ATR) | 12.12 | 7.56 |
| MACD | -3.61 | 0.96 |
| Stochastic Oscillator | 2.03 | 26.17 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Accenture is a leading IT services firm that provides consulting, system integration, and business process outsourcing to enterprises around the world. Customers of Accenture come from a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture is the world's largest professional services company by headcount with around 800,000 employees in over 120 countries.